“Potential anti-manic efficacy of a Kv3 channel modulator in a model of amphetamine-induced hyperactivity and in CLOCKΔ19 mutant mice” (Sidor et al.) Download Abstract
« Previous Page
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.
Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.
Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.